CONFERENCE LOCATION:
Jack & Sheryl Morris Cancer Center
165 Somerset Street
New Brunswick, NJ 08901
PARKING:
There are two free parking options:
Valet Parking: Available at 15 Division Street, New Brunswick.
Self-Parking: Available in the Hardenberg Street Garage (18 Hardenberg Street, New Brunswick). Take the third-floor skybridge directly into the Cancer Center
I am a hematologist-oncologist who specializes in treating patients with acute myeloid leukemia (AML), myelodysplastic syndromes and bone marrow transplantation. Every day, I collaborate with my colleagues at the OSUCCC – James to create targeted therapies for each patient. Cancer is complex, but I’m confident our research continues to bring us closer to finding a cure. It’s an honor to work at one of the nation’s premier cancer hospitals. Our collective expertise results in faster responses, fewer side effects and more hope for cancer patients everywhere.
Abstract The Dedicator of Cytokinesis1 (DOCK1) has been implicated in solid tumors; however, its precise role and therapeutic potential in acute myeloid leukemia (AML) remain largely unexplored. Here we investigated the prognostic significance and functional roles of DOCK1 in AML…
Highlight The 10-year incidence of non-cutaneous SM (6.8%) confirms its impact on late NRM. SM subtype distribution and timing vary by transplant: t-MDS/AML after auto-HCT, PTLD early after allo-HCT. PTLD declined markedly, nearly disappearing in the PTCy era with less ATG/Cord…
Abstract 6508 Background: Advances in hematopoietic stem cell transplantation (HSCT) have been driven by progress in supportive care, conditioning regimens, and graft-versus-host disease (GvHD) prophylaxis. Post-transplant morbidity and mortality are most pronounced in the first…
Haploidentical bone marrow transplantation (haplo-BMT) with post-transplant cyclophosphamide (PT-Cy) has become an established alternative for patients lacking HLA-matched donors, with outcomes comparable to those of matched-sibling and unrelated-donor transplants [1]. While CD34…
Abstract Background ASXL1 mutations (ASXL1MUT) are common in acute myeloid leukemia (AML) and have historically conferred an adverse prognosis with intensive chemotherapy. Given the increasing use of venetoclax (VEN)-based lower intensity therapy (LIT), the European LeukemiaNet…
To fully appreciate how quickly molecular analysis has transformed evaluation and treatment decisions in acute myeloid leukemia (AML), we need look no further than the seminal article by JP Patel et al. published in 2012 in The New England Journal of Medicine concerning the…
Abstract Developing chimeric antigen receptor (CAR) T cells for acute myeloid leukemia (AML) has been challenging due to a lack of known AML-associated antigens that spare normal hematopoietic precursor cells. Here we reasoned that donor autoantibodies from AML recipients cured…
